Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: First case report

Japanese Journal of Clinical Oncology

Volumn 31, Issue 6, 2001, Pages 284-286

  Kurakawa, Eri ^a   Kasuga, Ikuma ^a   Ishizuka, Shirou ^a   Yoshida, Tsuyoshi ^a   Kunisawa, Akira ^a   Minemura, Kazushige ^a   Utsumi, Kenta ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Anticancer drug; Interstitial pneumonia; TS 1

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; PREDNISONE; RABEPRAZOLE; RANITIDINE; REBAMIPIDE; TS 1;

AGED; ANOREXIA; ARTICLE; BLOOD; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTERSTITIAL PNEUMONIA; LYMPHOCYTE; LYMPHOCYTE TRANSFORMATION TEST; MALE; STOMACH CANCER; STOMACH LAVAGE; TREATMENT OUTCOME;

EID: 0034910860     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hye057     Document Type: Article

References (5)

1. Inhibitory effects of pyrimidine, barbituric acid and derivatives on 5-fluorouracil degradation in rat liver extracts
2. Inhibition by oxnic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
3. Complete response of a gastric primary after a short but toxic course of S-1
4. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers
5. Late phase II study of novel oral fluoropyrimidine anticancer drug TS-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients